Science Spotlight: How Denali’s CNS-penetrant amyloid mAb may avoid ARIA

Denali Therapeutics Inc. (NASDAQ:DNLI) revealed in Science a way to avoid a key safety issue of anti-amyloid-targeting mAbs by delivering therapeutic antibodies to the brain using receptor-mediated transport.

Traditional anti-amyloid mAbs for Alzheimer’s disease enter the brain through cerebrospinal fluid and perivascular spaces surrounding arteries, where vascular amyloid plaques reside, causing inflammation and brain swelling, measured as amyloid-related imaging abnormalities (ARIA), in mice and some patients...